^
Association details:
Biomarker:TP53 mutation
Cancer:Hepatocellular Cancer
Drug Class:PD1 inhibitor +
Angiogenesis inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody

Published date:
07/07/2022
Excerpt:
Baseline clinical data, blood samples, and imaging data of the first evaluation after two cycles of treatment were collected for 40 patients with advanced HCC...The high mutation frequency of TP53 and ARID1A appeared in the non-response cohort.
DOI:
10.3389/fimmu.2022.930096